Strs Ohio Decreases Stock Holdings in Liquidia Co. (NASDAQ:LQDA)

Strs Ohio decreased its position in Liquidia Co. (NASDAQ:LQDA - Free Report) by 88.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,600 shares of the company's stock after selling 70,400 shares during the quarter. Strs Ohio's holdings in Liquidia were worth $115,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fortitude Family Office LLC bought a new stake in shares of Liquidia in the fourth quarter valued at approximately $26,000. Aigen Investment Management LP bought a new stake in shares of Liquidia in the third quarter valued at approximately $80,000. SG Americas Securities LLC bought a new stake in shares of Liquidia in the third quarter valued at approximately $84,000. Cerity Partners LLC bought a new stake in shares of Liquidia in the fourth quarter valued at approximately $197,000. Finally, Simplicity Solutions LLC bought a new stake in shares of Liquidia in the third quarter valued at approximately $136,000. Institutional investors and hedge funds own 64.54% of the company's stock.

Liquidia Stock Down 1.4 %

Shares of LQDA traded down $0.19 during trading hours on Thursday, reaching $12.98. The stock had a trading volume of 478,304 shares, compared to its average volume of 936,585. Liquidia Co. has a 12 month low of $5.71 and a 12 month high of $16.99. The company's 50-day moving average is $14.42 and its two-hundred day moving average is $11.40.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.19). The company had revenue of $4.53 million during the quarter, compared to analyst estimates of $5.29 million. Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. As a group, sell-side analysts anticipate that Liquidia Co. will post -1.01 earnings per share for the current fiscal year.

Insider Activity at Liquidia

In related news, CEO Roger Jeffs sold 28,583 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $15.82, for a total value of $452,183.06. Following the completion of the sale, the chief executive officer now directly owns 835,345 shares in the company, valued at $13,215,157.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Jason Adair sold 4,657 shares of the firm's stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $15.81, for a total value of $73,627.17. Following the completion of the sale, the insider now directly owns 108,640 shares in the company, valued at approximately $1,717,598.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Roger Jeffs sold 28,583 shares of the company's stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $15.82, for a total value of $452,183.06. Following the transaction, the chief executive officer now directly owns 835,345 shares in the company, valued at $13,215,157.90. The disclosure for this sale can be found here. Insiders sold 70,999 shares of company stock worth $1,100,444 over the last three months. Company insiders own 31.60% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on LQDA. HC Wainwright upped their target price on Liquidia from $16.00 to $32.00 and gave the stock a "buy" rating in a research note on Thursday, March 14th. Needham & Company LLC restated a "buy" rating and set a $28.00 target price on shares of Liquidia in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $21.00.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).